{"entity":{"id":"paper-alfonso-racotumomab-maintenance-nsclc-ccr-2014","kind":"paper","name":"Racotumomab-alum vaccine as switch maintenance in advanced non-small cell lung cancer: a randomised placebo-controlled trial","aka":[],"tldr":"In 176 patients with advanced lung cancer whose disease was controlled by chemotherapy, the Cuban anti-idiotype vaccine racotumomab lengthened median survival from 6.8 to 8.2 months compared with placebo.","summary":"Published as \"A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients\". Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 ganglioside found on tumour cells. Patients with stage IIIb or IV disease that was at least stable after first-line chemotherapy were randomised 1:1 to the vaccine or placebo, with overall survival as the primary endpoint.","asOf":"2026-11-11","links":[{"label":"Clin Cancer Res 2014","url":"https://doi.org/10.1158/1078-0432.CCR-13-1674"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/24788102/"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["racotumomab"],"companies":["cimab"],"institutions":["inor-cuba","cencec-cuba"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Clinical Cancer Research","year":2014,"doi":"10.1158/1078-0432.CCR-13-1674","pmid":"24788102","authors":"Alfonso S, Valdés-Zayas A, Santiesteban ER, et al.","paperType":"rct","findings":["Median overall survival was 8.23 months with racotumomab-alum (87 patients) and 6.80 months with placebo (89 patients) (HR 0.63, 95% CI 0.46 to 0.87, P = 0.004).","Median progression-free survival was 5.33 against 3.90 months (HR 0.73, 95% CI 0.53 to 0.99, P = 0.039).","The commonest adverse events were burning and pain at the injection site, bone pain and asthenia."],"whatItMeans":"A second Cuban therapeutic vaccine for lung cancer with randomised evidence of a modest survival gain, in a setting where few patients received further treatment at progression.","caveats":["Only five patients per group received further anticancer therapy at progression, which differs from current practice where immunotherapy and later lines are standard.","The authors describe it as a preliminary estimate of efficacy."],"participants":176},"route":"/key-papers/paper-alfonso-racotumomab-maintenance-nsclc-ccr-2014/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"racotumomab","kind":"drug","name":"Racotumomab","route":"/drugs/racotumomab/"}],"company":[{"id":"cimab","kind":"company","name":"CIMAB","route":"/companies/cimab/"}],"institution":[{"id":"inor-cuba","kind":"institution","name":"Instituto Nacional de Oncología y Radiobiología (INOR)","route":"/institutions/inor-cuba/"},{"id":"cencec-cuba","kind":"institution","name":"National Coordinating Centre of Clinical Trials, Cuba (CENCEC)","route":"/institutions/cencec-cuba/"}]}}